SEC Form 4/A · accession 0000899243-16-019280
Aldeyra Therapeutics, Inc. · ALDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Todd C Brady
Officer — President and CEO · Director
Period of report
Mar 16, 2016
Accepted (ET)
May 5, 2016 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001341235
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $4.59 | Mar 16, 2016 | A | 250,000 | A | — | Mar 16, 2026 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1The number of shares of common stock covered by this option grant inadvertently exceeded a limitation applicable to option awards under the Issuer's 2013 Equity Incentive Plan, and 50,000 excess options were rescinded. This amended Form 4 reflects the corrected number of stock options granted. Except as otherwise stated above, the vesting and other terms and conditions of the option will remain unchanged.
- F2The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2016.